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Abstract The prevalence of cardiovascular diseases rises
with aging and is one of the main causes of mortality in
western countries. In view of the progressively aging
population, there is an urge for a better understanding of
age-associated cardiovascular diseases and its underlying
molecular mechanisms. The risk factors for cardiovascular
diseases include unhealthy diet, diabetes, obesity, smoking,
alcohol consumption, physical inactivity, and aging. Increased
production of oxygen-derived free radicals plays an important
role in mediating cardiovascular diseases. Oxidative stress
affects the availability and/or balance of key-regulators of
vascular homeostasis and favors the development of cardio-
vascular diseases. Reactive oxygen species are generated by
different intracellular molecular pathways principally located
in the cytoplasm and in the mitochondria. The mitochondrial
protein p66Shc and the deacetylase enzyme SIRT1 were
shown to be involved in different aspects of cardiovascular
diseases. This review focuses on the latest scientific advances
in understanding cardiovascular diseases associated to aging,
as well as delineating the possible therapeutic implications of
p66Shc and SIRT 1 in this process.
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Introduction
To date, cardiovascular disease is the leading cause of death
in western countries. Although the absolute incidence and
mortality of cardiovascular disease are falling, figures are
still very high. Thus, there is an urge for more efforts by the
scientific community to identify new mediators and/or
novel therapeutic targets for cardiovascular disease.
Cardiovascular disorders are a heterogeneous entity
encompassing risk factors such as hypertension, diabetes,
smoking, obesity, and aging, as well as true cardiac conditions
such as coronary artery disease, infarction, and heart failure.
However, certain traits seem to be a common denominator to
different cardiovascular conditions. Usually, endothelial dys-
function is the earliest disturbance. However, it is rather
difficult to be diagnosed before symptoms develop. The
present nonexhaustive review discusses some of the latest
scientific advances at the molecular level.
Elevated oxidative stress and vascular dysfunction
The endothelium, the innermost layer of the vascular wall,
offers a primary protection against vascular dysfunction,
occurrence of atherosclerosis, and thrombogenesis. Under
physiological conditions, a balance between reactive oxy-
gen species (ROS) damage and endothelial progenitor cell-
mediated repair keeps the integrity of endothelium and
maintains endothelial functions [20]. However, under
pathophysiological conditions, this balance shifts towards
ROS-induced damage, which is due to additional cellular
damage by protein oxidation and/or decreased endothelial
progenitor cells’ function [6, 32] (Fig. 1).
Nitric oxide (NO), the principle endothelial-derived
relaxing factor [38, 107], possesses inhibitory effects on
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endothelium-derived contracting factors [38, 107]. When
the release of NO is reduced and the production of
endothelium-derived contracting factors is enhanced, endo-
thelial dysfunction ensues [107]. In addition, NO plays a
key role in preventing atherosclerosis by reducing the
adhesion of platelets and leukocytes [8, 33] and by
inhibiting the migration and proliferation of smooth muscle
cells [69].
A large body of evidences reports a reduced blood flow
in aged people or patients with hypertension, hypercholes-
terolemia, atherosclerosis, heart failure, or diabetes [56, 59,
83]. This phenomenon is also observed in pertinent animal
models and is associated with a reduced NO bioavailability
and/or an enhanced endothelium-dependent vasoconstric-
tion [7, 43, 91, 108]. These studies confirm endothelial
dysfunction observed in cardiovascular disorders in
human.
The elevated levels of superoxide anion (O2
−) observed
under disease conditions are a crucial factor for the loss of
NO availability in endothelial cells since the expression of
endothelial nitric oxide synthase (eNOS) in diseases is
either declined [26] or preserved [92]. Superoxide anion
inactivates NO in a few seconds resulting in the generation
of another highly reactive species, peroxynitrite (ONOO−).
Peroxynitrite penetrates across the phospholipid membrane
and produces substrate nitration, thereby, damaging DNA
[98], modifying lipoproteins by oxidation [82], disrupting
mitochondrial function [57, 58, 97], and depleting plasma
antioxidants [106].
The increased production of ROS under disease con-
ditions is also implicated in proinflammatory processes by
directly acting as second messengers. For instance, ROS
activate NF-κB, a key transcription factor [27]. Activation
of NF-κB, in turn, promotes the transcription of several
critical genes for atherogenesis including cytokines such as
tumor necrosis factor-α (TNF-α), interleukin 6 (IL-6),
monocyte chemoattractant protein-1 (MCP-1), and adhe-
sion molecules (VCAM-1) [14, 28, 29, 39, 47, 50, 52].
Thus, oxidative stress is regarded as a key factor contrib-
uting to chronic inflammation [27].
Oxidative stress in cardiovascular disease
A large body of evidences underscores a critical role for
oxygen free radicals in endothelial injury, aging, and cardio-
vascular diseases [17, 24, 31, 55, 107]. Aging shares several
molecular features with cardiovascular diseases [16, 94]. The
free radical theory of aging is widely accepted as the
reference concept describing the mechanism underlying aging
and aging-related diseases [26, 35, 41, 42, 75, 84, 105].
Increased production of ROS in aging is associated with
enhanced ONOO− formation [105], up-regulated expression
of inducible nitric oxide synthase (iNOS) [26], NAD(P)H
oxidase [2], and/or a parallel down-regulation of antioxidants
such as extracellular SOD [48] and decreased catalase activity
[92].
The development of atherosclerosis is considered to be
the result of chronic inflammation mostly induced by the
increased production of ROS. The principal sources of free
radical species in atherosclerosis are iNOS [30, 113], NAD
(P)H oxidase [111], and/or cyclooxygenase-2 [5], since
these proteins are expressed in atheromatous plaques.
Importantly, ROS modify lipoproteins to the oxidized form,
e.g., oxidized low-density lipoprotein (oxLDL), which has
profound biological effects via the LOX-1 receptor in
endothelial cells and the scavenger receptor-A in macro-
phages [3, 40, 100, 118]. In addition to the decrease in
eNOS activity [36, 89, 101], oxLDL increases the expres-
sion of VCAM-1 and MCP-1 protein through NF-κB-
mediated gene transcription [3, 22]. This implies an
intricate ROS-mediated inflammation in the occurrence of
atherosclerosis.
Diabetes is a major risk factor for cardiovascular
diseases [31]. The increased production of free radicals
observed in diabetes results from reduced activity of
superoxide dismutase [19, 22, 89, 96, 101], reduced
expression of heme oxygenase [19], as well as from
enhanced expression of NAD(P)H oxidase [62, 69, 112]
and cyclooxygenase [60, 61, 91]. In addition, the unique
glycation reaction in diabetes generates, yet, more oxidative
free radicals through intermediate compounds that in turn
increase the levels of reactive oxygen species [31, 45, 46,
87, 88, 95, 103, 119, 121]. Dicarbonyl compounds such as
methyglyoxal and 3-deoxyglucosone and intermediate
products of glycation are typical examples. The serum
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Fig. 1 With aging and cardiovascular diseases, the balance between
noxious insults and protective systems is progressively lost favoring
the development of endothelial dysfunction and vascular disease. ROS
reactive oxygen species, NO nitric oxide
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concentrations of both methyglyoxal and 3-deoxyglucosone
are increased in patients with diabetes mellitus [99] indicating
that free radicals play a crucial role in the pathogenesis of
diabetes-associated complications [103, 114].
The ROS sensitive protein p66Shc
The mitochondrial adaptor protein p66Shc is regarded as an
important mediator of aging since genetic deletion of
p66Shc protein in the mouse causes lower levels of ROS
and prolongs lifespan by 30% [66]. The mammalian Shc
locus encodes for three different ShcA adaptor proteins
with respective molecular masses of 46, 52, and 66 kDa.
The splice variant p66Shc is the only isoform to participate
in mitochondrial ROS generation and thus, to translate
oxidative signals into apoptosis [12, 51, 66, 72]. In fact, in
the absence of p66Shc, mitochondrial oxidative phosphoryla-
tion is reduced in favor of glycolysis. In light of its pivotal role
in ROS generation, many efforts have been made to
investigate the pathophysiological relevance of p66Shc in
ROS-mediated diseases [18, 23].
The expression pattern of p66Shc protein in humans
was studied in young people, elderly, and centenarians.
The expression of p66Shc in fibroblasts was shown to
increase with age [79] suggesting that the expression of
p66Shc protein concurs with the process of aging. In
human peripheral blood monocytes, p66Shc messenger
RNA expression is enhanced in diabetic patients compared
to healthy subjects [78]. Given the up-regulated expres-
sion of p66Shc in aged people and in diabetic patients, the
hypothesis that this mitochondrial adaptor protein p66Shc
is linked to aging and/or ROS-related diseases is widely
accepted. Genetically modified mice are a useful tool to
study the role of p66Shc protein under pathophysiological
conditions since identical Shc genomic organization, tran-
script assembly, as well as, a high degree of amino acid
identity have been reported in mice and in humans [67].
In adipose cell culture experiments, insulin treatment
increased the production of ROS in brown preadipocytes
from wild type mice, but not in those from p66Shc
knockout mice. Reintroduction of p66Shc expression ex
vivo restored the insulin-stimulated ROS production in
preadipocytes of p66Shc knockout mice, confirming that
p66Shc plays a crucial role in ROS production [9].
Further, p66Shc knockout mice are resistant to high fat
diet-induced obesity, which is shown as increased basal
metabolism, reduced fat development, and increased
insulin sensitivity of peripheral tissues [9]. These results
imply that p66Shc is an important mediator of insulin-
signaling pathway, as well as energetic metabolism.
In line with the above, a blunted age-dependent and NO-
mediated vasodilatation was maintained in the aorta of age-
matched p66Shc knockout mice (Fig. 2) demonstrating that
a preserved NO bioavailability in aged p66Shc knockout
mice is due to lower aortic O2
− levels and reduced aortic
3-nitrotyrosine content [37]. Preserved NO availability in
aged p66Shc knockout mice was shown to be dependent on
a reduced ROS production and a consequently reduced
scavenging [37].
The beneficial effects of p66Shc protein deletions are
also observed in apoE knockout mice [18, 71]. High fat diet
induces comparably high levels of serum lipid in both
control and p66Shc knockout mice. However, the level of
lipid peroxidation is lower in p66Shc knockout mice
compared to control mice. This suggests a putative role of
p66Shc in the oxidation modification of lipoprotein.
Seemingly, p66Shc knockout mice are protected from high
fat diet-induced aortic lesion due to a decreased oxidative
stress and a decreased formation of foam cells [71]. These
data indicate that p66Shc takes part in the development of
ROS-mediated atherosclerotic lesion.
Fig. 2 a Age-induced changes in endothelium-dependent relaxation
of WT and p66shc-/- aortas. Lines graph showing concentration–
response curves to acetylcholine. Results are presented as mean±
SEM; n=7 in each group. M/L indicates mol/L. The symbol (*)
indicates p<0.05 versus young WT. b Bar graph showing peak
concentrations of NO in young (gray bars) and old (black bars) WT
and p66shc-/- mice, respectively. Results are presented as mean±
SEM; n=4 to 6 in each group. The symbol (*) indicates p<0.05 versus
young WT [84]
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In line with the observation that p66Shc expression is
increased in diabetic patients [78], the expressions of p66Shc
protein is enhanced in the aorta and the renal cortex of
streptozotocin-induced type I diabetic mice [19, 64]. Glucose
levels in serum were comparable in diabetic p66Shc
knockout and wild type mice [19, 64, 65], indicating that
the deletion of p66Shc protein does not affect the diabetic
condition and the hyperglycemia. Nevertheless, p66Shc
knockout mice are protected from diabetes-induced endothe-
lial dysfunction [19] and diabetic glomerulopathy [65],
which is due to reduced production of ROS and a decreased
cellular apoptosis (Fig. 3). The above-described data
underscore the pivotal role of p66Shc in diabetes-induced
ROS production [19].
The energy sensor—SIRT1
SIRT1 belongs to histone deacetylase class III, which
reverses protein acetylation and promotes DNA stability.
SIRT1 also deacetylates a number of nonhistone target
protein, including tumor suppressor p53 protein [54, 109],
members of the Forkhead transcription factor family
(FoxO) [15, 73, 104, 116], stress response protein ku70
and NF-κB [21, 117], and metabolic regulator PCG-1α
[86]. Owing to a unique nicotinamide adenine dinucleotide
(NAD+)-dependent enzymatic activity, SIRT1 was recently
considered as a promising therapeutic approach for aging
and aging-associated cardiovascular diseases [93].
Starvation enhances the expression of SIRT1 protein in
mouse liver and in human peripheral blood mononuclear
cell, which returns to normal level upon feeding [73, 86].
The up-regulated SIRT1 protein deacetylates PGC-1 α in a
NAD+-dependent manner in both hepatic cells and mice
livers, indicating a regulatory role of Sirt1 in the gluconeo-
genic/glycolytic pathway [86]. In a mouse model of chronic
calorie restriction, which extends lifespan, the expression of
SIRT1 protein is elevated in the calorie-restricted group
[74]. Likewise, mice overexpressing SIRT1 share a similar
phenotype to calorie-restricted mice, including lower body
weight, lower cholesterol level, improved glucose homeo-
stasis, and increased metabolic rate [13]. Thus, SIRT1 is an
important mediator of the beneficial effects observed with
calorie restriction and is probably involved in lifespan
control.
The presence of SIRT1 protein was also observed in
pancreatic β cell [70]. In cell culture experiments,
inhibition of SIRT1 reduced the secretion of insulin
suggesting that SIRT1is a possible target to insulin
secretion [70]. In SIRT1 knockout mice, insulin levels are
reduced in both normoglycemic and glucose tolerance
experiments. Consistently, in a type II diabetic mouse,
genetic up-regulation of SIRT1 [13, 76] or treated with
resveratrol [68], a small molecule activator of SIRT1,
enhances insulin secretion, and thus, improves glucose
tolerance. These data underscore that the activator of SIRT1
is a potentially therapeutic principle for diabetes, especially
for insulin-resistant type II diabetes.
SIRT1 also has beneficial effects on endothelial cells. In
rat aorta, inhibition of SIRT1 ex vivo causes a blunted
endothelium-dependent relaxation. Restoration of SIRT1
increases eNOS expression by deacetylation on both lysine
496 and 506 indicating that SIRT1 directly regulates eNOS
[63]. In apoE knockout mice fed with high fat diet, the
mouse overexpressing endothelial cell-specific SIRT1
maintains relaxation in the aorta accompanied by up-
regulated eNOS and a retarded atherogensis [122]. This
result confirms a protective role of SIRT1 and eNOS for the
Fig. 3 a Bar graphs showing ONOO− levels determined by
chemiluminescence. Results are presented as mean±SEM; n=6 in
each group. p<0.05 versus control WT mice; p<0.05 versus control
WT mice. Immunostaining of nitrotyrosine residues in aortas from
control and diabetic WT and p66Shc-/- mice is shown. b Bar graphs
showing thiobarbituric acid-reactive substances levels in aortas from
control and diabetic WT and p66Shc-/- mice. Results are presented as
mean±SEM; n=4 in each group. The symbol (*) indicates p<0.05
versus control WT mice; p<0.05 versus control WT [58]
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development of atherosclerosis. Nevertheless, NO donor
increases SIRT1 expression and delays cell senescence in
human endothelial cells [77]. Calorie restriction fails to
enhance SIRT1 expression in eNOS knockout mice [74],
suggesting that NO may also directly modulate SIRT1
expression.
In the aorta of streptozotocin-induced diabetic mouse,
the expression of SIRT1 protein is reduced accompanied by
higher levels of acetylated p53 and p21 expression [76].
Resveratrol restores acetylated p53 and p21 in the aorta and
thus, improves endothelial dysfunction by down-regulating
ICAM-1 expression and inhibiting leukocyte rolling [76],
These data suggest a protective role for SIRT1 in the
pathogenesis of diabetic vascular dysfunction.
In transgenic mice with heart-specific overexpression of
SIRT1, beneficial effects are observed only in animals with
a slight or moderate up-regulation of SIRT1, which is due
to an increased catalase expression through FoxO-
dependent signaling. Furthermore, the heart-specific over-
expression of SIRT1 retards aging of the heart and further
protects the heart from paraquat-induced oxidative stress
[4].
Clinical perspective
The proteins discussed in the present review represent
different therapeutic targets for treatments of cardiovascular
diseases, reducing cell damage or enhancing cell defenses.
The p66Shc protein is strongly linked to the generation
of ROS. Genetic deletion of p66Shc prevents ROS-
mediated cell damage and by doing so reduces cellular
apoptosis. Since the antioxidant treatments proposed to
decreases cardiovascular events failed to reduce the risk of
cardiovascular events in large long-term clinical trials [53, 90,
110], the inhibition of p66Shc seems to be a more attractive
therapeutic option to reduce oxidative stress in humans.
SIRT1 exerts multiple protective effects. Physical training
is reported to restore SIRT1 protein in both heart and adipose
tissue of aged mice [34] supporting the beneficial effect of
exercise training [1, 10, 11, 34, 81, 85, 102]. Resveratrol,
one of the polyphenolic compounds in grapes and wine, is
reported as a small molecule activator of SIRT1 [44, 49].
Resveratrol increases insulin secretion in pancreatic β cells
[68] and improves endothelial function in the aorta of
diabetic mouse [76]. Besides, resveratrol reduces TNF-α-
induced tissue factor expression through inactivation of NF-
κB-mediated transcription [80] and thus, prevents cells’
adhesiveness [25, 120]. In addition, resveratrol delays cell
senescence via PI3K-Akt pathway in endothelial progenitor
cells [115].
Summary and conclusions
The p66Shc is a mitochondrial protein mediating oxidative
stress. The inhibition of p66Shc reduces oxidative stress,
suggesting that p66Shc is a promising target to reduce
ROS-mediated cardiovascular disease. SIRT1 is a protein
sensitive to energy change in metabolism and improves cell
survival and functions by deacetylating regulatory proteins.
Up-regulation of SIRT1 exhibits multiple beneficial effects
on endothelial dysfunction especially in diabetes. It may be
considered optimistic to assume that simply down-
regulating p66Shc, up-regulating SIRT1, or a combination
of the two will effectively slow down aging in humans and
Fig. 4 Schematic representation of the endothelium and some of its
key derived vasoactive substances. Different stress stimuli (e.g.,
glucose, oxLDL, and angiotensin II) and occurrence of aging enhance
the production of O2− and determine endothelial dysfunction. p66Shc
is principally located in the mitochondria where it contributes to the
production of O2−, which scavenges NO, and activates NF-κB and
p53. Sirt1 deacetylates nitric oxide synthase, thus, restores NO
availability. Sirt1 also deacetylates p53 and consequently, reduces cell
apoptosis. The symbol (⊕) indicates activation while (⊖) indicates
inhibition. oxLDL oxidized low density lipoprotein, NOS NO
synthase, NO nitric oxide, MCP-1 monocyte chemotactic protein-1,
ICAM intercellular adhesion molecule, VCAM vascular cells adhesion
molecule, NF-κB nuclear factor-kappa B, NADPH nicotinamide
adenine dinucleotide phosphate-oxidase, Deacetyl deacetylation
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shift the pathophysiological imbalance towards a normalized
condition. Nevertheless, these recently discovered target
proteins offer insights to better characterize underlying
mechanisms of cardiovascular diseases and aging (Fig. 4).
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